However, the mother will need to be retreated with Rho D immune globulin during that pregnancy to prevent a primary anti-Rh antibody response that could threaten subsequent pregnancies. The results reveal that Kerry has proteinuria abnormal protein levels in the urine , hemoglobinuria excess hemoglobin in the urine , and a low hematocrit RBC count.
These tests suggest that Kerry is suffering from a mild bout of hemolytic anemia. The physician suspects that the problem might be autoimmune, so she refers Kerry to a rheumatologist for additional testing and diagnosis. Type III hypersensitivities are immune-complex reactions that were first characterized by Nicolas Maurice Arthus — in To produce antibodies for experimental procedures, Arthus immunized rabbits by injecting them with serum from horses. However, while immunizing rabbits repeatedly with horse serum, Arthus noticed a previously unreported and unexpected localized subcutaneous hemorrhage with edema at the site of injection.
This reaction developed within 3 to10 hours after injection. This localized reaction to non-self serum proteins was called an Arthus reaction. An Arthus reaction occurs when soluble antigens bind with IgG in a ratio that results in the accumulation of antigen-antibody aggregates called immune complexes. A unique characteristic of type III hypersensitivity is antibody excess primarily IgG , coupled with a relatively low concentration of antigen, resulting in the formation of small immune complexes that deposit on the surface of the epithelial cells lining the inner lumen of small blood vessels or on the surfaces of tissues.
This immune complex accumulation leads to a cascade of inflammatory events that include the following:. Activation of coagulation pathways also occurs, resulting in thrombi blood clots that occlude blood vessels and cause ischemia that can lead to vascular necrosis and localized hemorrhage. Systemic type III hypersensitivity serum sickness occurs when immune complexes deposit in various body sites, resulting in a more generalized systemic inflammatory response.
These immune complexes involve non-self proteins such as antibodies produced in animals for artificial passive immunity see Vaccines , certain drugs, or microbial antigens that are continuously released over time during chronic infections e.
The mechanisms of serum sickness are similar to those described in localized type III hypersensitivity but involve widespread activation of mast cells, complement, neutrophils, and macrophages, which causes tissue destruction in areas such as the kidneys, joints, and blood vessels. As a result of tissue destruction, symptoms of serum sickness include chills, fever, rash, vasculitis, and arthritis.
Development of glomerulonephritis or hepatitis is also possible. Autoimmune diseases such as systemic lupus erythematosus SLE and rheumatoid arthritis can also involve damaging type III hypersensitivity reactions when auto-antibodies form immune complexes with self antigens. These conditions are discussed in Autoimmune Disorders. Antibacterial sera are much less commonly used now than in the past, having been replaced by toxoid vaccines.
However, a diphtheria antitoxin produced in horses is one example of such a treatment that is still used in some parts of the world.
Although it is not licensed by the FDA for use in the United States, diphtheria antitoxin can be used to treat cases of diphtheria, which are caused by the bacterium Corynebacterium diphtheriae. Serum sickness can occur when the patient develops an immune response to non-self horse proteins. Immune complexes are formed between the horse proteins and circulating antibodies when the two exist in certain proportions.
These immune complexes can deposit in organs, causing damage such as arthritis, nephritis, rash, and fever. Serum sickness is usually transient with no permanent damage unless the patient is chronically exposed to the antigen, which can then result in irreversible damage to body sites such as joints and kidneys.
Kerry does not make it to the rheumatologist. She is quickly rushed to the emergency department, where her primary care physician relates her medical history and recent test results. The emergency department physician calls in the rheumatologist on staff at the hospital for consultation.
Based on the symptoms and test results, the rheumatologist suspects that Kerry has lupus and orders a pair of blood tests: an antinuclear antibody test ANA to look for antibodies that bind to DNA and another test that looks for antibodies that bind to a self-antigen called the Smith antigen Sm. Type IV hypersensitivities are not mediated by antibodies like the other three types of hypersensitivities.
Rather, type IV hypersensitivities are regulated by T cells and involve the action of effector cells. These types of hypersensitivities can be organized into three subcategories based on T-cell subtype, type of antigen, and the resulting effector mechanism.
The sensitization step involves the introduction of antigen into the skin and phagocytosis by local antigen presenting cells APCs.
Upon subsequent exposure to the antigen, these sensitized memory T H 1 cells release cytokines that activate macrophages, and activated macrophages are responsible for much of the tissue damage.
Examples of this T H 1-mediated hypersensitivity are observed in tuberculin the Mantoux skin test and contact dermatitis , such as occurs in latex allergy reactions.
In the second type IV subcategory, CD4 T H 2-mediated reactions result in chronic asthma or chronic allergic rhinitis.
In these cases, the soluble antigen is first inhaled, resulting in eosinophil recruitment and activation with the release of cytokines and inflammatory mediators. In the third type IV subcategory, CD8 cytotoxic T lymphocyte CTL -mediated reactions are associated with tissue transplant rejection and contact dermatitis.
Austrian pediatrician Clemans von Pirquet — first described allergy mechanisms, including type III serum sickness. The device Pirquet used was similar to the tine test device with four needles seen in Figure 8. The tips of all the needles in the array are coated with tuberculin, a protein extract of TB bacteria, effectively introducing the tuberculin into the skin.
One to 3 days later, the area can be examined for a delayed hypersensitivity reaction, signs of which include swelling and redness. As you can imagine, scarification was not a pleasant experience, [10] and the numerous skin punctures put the patient at risk of developing bacterial infection of the skin. A positive test, which is indicated by a delayed localized swelling at the injection site, does not necessarily mean that the patient is currently infected with active TB.
Because type IV delayed-type hypersensitivity is mediated by reactivation of memory T cells, such cells may have been created recently due to an active current infection or years prior if a patient had TB and had spontaneously cleared it, or if it had gone into latency. However, the test can be used to confirm infection in cases in which symptoms in the patient or findings on a radiograph suggest its presence. Some disease caused by hypersensitivities are not caused exclusively by one type.
For example, hypersensitivity pneumonitis HP , which is often an occupational or environmental disease, occurs when the lungs become inflamed due to an allergic reaction to inhaled dust, endospores, bird feathers, bird droppings, molds, or chemicals.
HP goes by many different names associated with various forms of exposure. Repeated exposure to allergens can cause alveolitis due to the formation of immune complexes in the alveolar wall of the lung accompanied by fluid accumulation, and the formation of granulomas and other lesions in the lung as a result of T H 1-mediated macrophage activation.
Alveolitis with fluid and granuloma formation results in poor oxygen perfusion in the alveoli, which, in turn, can cause symptoms such as coughing, dyspnea, chills, fever, sweating, myalgias, headache, and nausea.
Symptoms may occur as quickly as 2 hours after exposure and can persist for weeks if left untreated. The table below summarizes the mechanisms and effects of each type of hypersensitivity discussed in this section. Diagnosis of type I hypersensitivities is a complex process requiring several diagnostic tests in addition to a well-documented patient history.
Serum IgE levels can be measured, but elevated IgE alone does not confirm allergic disease. As part of the process to identify the antigens responsible for a type I reaction allergy, testing through a prick puncture skin test PPST or an intradermal test can be performed. The second type of testing, the intradermal test, requires injection into the dermis with a small needle.
This needle, also known as a tuberculin needle, is attached to a syringe containing a small amount of allergen. Both the PPST and the intradermal tests are observed for 15—20 minutes for a wheal-flare reaction to the allergens. Type III hypersensitivities can often be misdiagnosed because of their nonspecific inflammatory nature. The symptoms are easily visible, but they may be associated with any of a number of other diseases. A strong, comprehensive patient history is crucial to proper and accurate diagnosis.
Tests used to establish the diagnosis of hypersensitivity pneumonitis resulting from type III hypersensitivity include bronchoalveolar lavage BAL , pulmonary function tests, and high-resolution computed tomography HRCT. Anyone concerned about an injury, illness or allergic reaction should contact a healthcare provider. Consumers who have purchased this product are urged not to consume them. This product should be thrown away or returned to the place of purchase.
For consumers not allergic to soy, there is no safety issue with this product. We sincerely apologize for any inconvenience this action represents to both our consumers and retail customers. For consumer support and product questions, please contact us here or call Other authors suggest that the altered mechanism contributing to increased IgE levels may be a deficient apoptosis rate of B cells after the switch to IgE.
They also suggest that IgG4-switched B memory cells might occasionally undergo a secondary switch to IgE on chronic allergen exposure Upon re-exposure to a multivalent allergen, attached IgE is cross-linked and cells become activated.
Within minutes of allergen re-exposure, cells release a series of preformed mediators, which leads to the acute phase characteristic of the allergic reaction. Activation also results in the synthesis and secretion of lipid mediators and cytokines fig. Figure 3. This regulation leads to a permanent cell sensitization that maintains the capacity of these cells to mount an immediate response after a new contact with an allergen When DCs are located in an inflammatory environment different from the initial one, new specific T helper cells will be generated with different effector functions, contributing to the appearance of new symptoms.
In addition to professional antigen presenting cells, mast cells and activated eosinophils internalize allergens through the IgE attached to the receptor and subsequently act as antigen-presenting cells activating the specific T effector cells, helping to perpetuate the process 4, Mast cells and basophils also express low-affinity and, under specific conditions, high-affinity IgG receptors.
Binding of IgE to CD23 on B cells facilitates allergen presentation to T cells, resulting in preferent immune responses to the allergen and exercising a positive feedback control.
However crosslinking of CD23 results in the down-regulation of IgE synthesis 3. IL-4 was shown to induce expression of CD23 on the surface of intestinal epithelial cells, allowing rapid internalization and transcytosis of IgE-allergen complexes from intestinal lumen to the underlying tissue to stimulate local hypersensitivity reactions Mast cells are widely recognized as immune effector cells that initiate innate immunity against pathogens.
They are essential in host defense against helmints and also are the major effectors of IgE-associated allergic disorders Recently it has been hypothesized that mast cells also contribute to the initiation and regulation of adaptive immune responses 4, Through the release of mediators, mast cells modulate different immune processes. That is the case of histamine, the main proinflammatory mediator of these cells.
This molecule participates in the early-phase of allergic response, primarily binding to H1 receptor. In addition to these effects histamine, regulates several essential events in the immune response , Through its H1, H3 and H4 receptors expressed on DCs, histamine acts as a positive stimuli that increases antigen presentation, proinflammatory cytokine production and promotes Th1 differentiation On the contrary, through the H2 receptor histamine inhibits antigen presentation and acts as a suppressor of IL production whereas enhances IL release which polarize a Th2 response 72, Histamine can also bind to receptors expressed on lymphocytes and regulates antigen-specific Th1 and Th2 cell as well as related antibody isotype response Binding of histamine to the H4 receptor produces a chemotactic action for mast cells and eosinophils, favoring their extravasation and activation , As has been previously mentioned, prostaglandin, E2 prostaglandin D2 and cysteinyl leukotrienes are potent inductors of DC2.
In addition mast cells can act as antigen presenting cells. Activated mast cells liberate different type Th2 cytokines and determine an environment where dendritic cells promote differentiation of new Th2 lymphocytes, favoring the allergic inflammatory process Mast cells also express Toll-like receptors, which may further accentuate their role in the immune-inflammatory response Then cells leave lymphatic tissue and enter the blood stream besides resting until their migration to the anatomic place where the allergen is found.
In the tissue, DCs and the local macrophages present small peptide fragments epitopes in conjunction with major histocompatibility complex MHC class II, to the Th2 cells, leading to T cell proliferation and activation. As a consequence, T cells release cytokines and increase their affinity for the tissue matrix, being retained inside the affected tissue while the antigen persists. Th2 cell activation promotes a delayed hypersensitivity reaction in which the main effector cell is eosinophil, and presents different characteristics in function of affected tissue.
This cellular response is responsible for late phase reaction and underlies most of the chronic allergic process, playing an essential role in the physiopathology of eosinophilic gastroenteropathies and in allergic asthma 7, It is assumed that allergen specific T lymphocytes express on their surface adhesion molecules, which permit their selective migration into the organ where the sensitization was produced. However, specific T lymphocytes to digestive allergens have been seen to express on their surface cutaneous lymphocyte antigen CLA , a skin-specific homing receptor , This justifies the emergence of inflammatory symptoms on the skin after the ingestion of food allergens.
It is important to emphasize that for induction of immediate response the presence of the complete allergen is required, while the activation of the T lymphocyte only needs the presence of determined peptides It has been shown that the delivery of synthetic peptides representing T cell epitopes of the allergen, but lacking of IgE epitopes, could induce strong T cell- mediated inflammatory responses , This response was induced in the absence of preceding IgE-mediated events.
These observations reveal that T lymphocytes can be activated and induce an allergic syndrome through IgE non-dependant mechanisms. It is possible that this process has parallelism with the mechanisms by which some drugs are capable of directly attaching the receptor of different types of T cells and activating them, through mechanisms dependant on MHCII without the need for a previous sensitization , In this line it has been observed that during the digestive process, peptides which do not contain epitopes for the IgE but preserve those recognized by T cells are generated It has been proposed that this digestive peptides may be able to induce both local and systemic inflammatory response, mediated solely by the activation of T lymphocytes, in absence of IgE Additionally, when administered systemically at low dose, peptides may induce long-lasting hyporesponsiveness in the T cell compartment through a mechanism that is associated with induction of IL In the same way, the use of peptides-based allergen preparation for immuntherapy results in the induction of tolerance, but gives rise to adverse reactions in a high proportion of patients Th2 lymphocyte activation induces the release of cytokines taking part in the inflammatory response through different actions.
IL-5 contributes to the differentiation of the eosinophils and basophils in bone marrow, promotes the release of substances chemotactic to these cells eotaxin, eotaxin2 eotaxin3 and RANTES and maximizes their action But this interleukin also activates the eosinophil in absence of IgE, which justifies the appearance of symptoms due to the activation with specific peptides for Th2 receptors.
IL-4 promote the synthesis of local and systemic IgE and inhibit the effector response of the macrophage; under such conditions new sensitizations produced will be Th2 type. IL stimulates mucus secretion and fibrosis that contributes to the perpetuation of tissue damage. IL-9 is a stimulator of the proliferation and differentiation of mast cells and eosinophils ILE also named IL , is a new identified interleukin, mainly produced by Th2 lymphocytes that seemed to be directly implicated in Th2-associated allergic inflammation.
The activation of the eosinophils provokes its degranulation and the liberation of inflammation mediators, some common and some different to those released by mast cell fig. Once activated, the eosinophil expresses MHCII and costimulator molecules enable it to become an antigen presenting cell, feeding back the inflammatory process The main difference is that the eosinophils granules do not contain histamine but release molecules toxic to the tissue, such as the major basic protein, and the eosinophil cationic protein, or different peroxidases and hydrolases or oxygen reactive species.
These mediators degrade cells in the tissue, rendering a dysfunction of the affected organ. On the other hand, eosinophils liberate fibrogenic factors and growth factors, which take part in tissue repairing. When the damage is sustained, the repairing response may be excessive and provoke a fibrotic syndrome that contributes significantly to the syndrome perpetuation. The contribution of Th1 cells in the pathology of allergy is more controversial since, conceptually, Th1 cytokines act as a counter-regulating Th2 response In addition, the experimental induction of a Th1 response against respiratory allergens elicits an inflammatory process in which macrophages and neutrophils are the effector cells.
This exclusive Th1 response does not produce any manifestation of allergic asthma. When Th2 cells are inhibited, the presence of specific Th1 cells reduce allergic inflammation, but the concurrent expression of Th1 and Th2 interleukins exacerbates the symptoms, mainly in chronic processes.
This suggests that once a Th2 cell response has been established, Th1 counter-regulation is more complex. Patients with atopic dermatitis exhibit a biphasic helper T-cell pattern in which Th2 immune response appears early in the acute phase, but progresses to a Th1 profile as chronic lesions emerge. An eczematous injury is caused in which essentially IgE does not take part The pathophisiological base of this change has recently been described The resulting activation of Th2 cells promotes IgE expression and induces a cell mediated response in which eosinophils are the effector cells.
DCs also migrate to the lymphatic tissue, sensitizing new lymphocytes to a Th2 phenotype. After the attachment of IgE on DCs, different interleukins and chemokines are released, which specifically attract IDECs inflammatory dendritic epidermal cell to the site of inflammation.
Later, specific Th1 activation in the skin or in other tissues is responsible for a cellular response mainly mediated by macrophages and neutrophils that change the clinical expression of the disease. Few inflammatory diseases have been associated with an exclusive induction of a specific Th1 response against external antigens.
Among them, celiac disease is a pathology in which a Th1 and T citototoxic Tc response is produced against the gliadin fraction of wheat, barley, rye and oats Several groups have described the activation of Th1 lymphocytes mediated by different drugs, which give place to a delayed hypersensitivity reaction In the Heiner Syndrome, a chronic pulmonary inflammatory process is produced, associated to the presence of precipitins specific against milk proteins Chronic inhalation of large amounts of some antigens induces allergic alveolitis mediated by high IgG levels, such as in Farmer's lung actinomyces and molds , or pigeon breeder's disease bird droppings 5.
Different studies support evidence for the contribution of T cytotoxic Tc cells in the pathogenesis of allergic diseases. Tc have been divided into two subsets that secrete Th1 or Th2 cytokines Tc1 or Tc2 cells respectively , however both induce similar inflammatory reactions including cytotoxicity and induction of delayed type hypersensitivity reaction with edema and granulocytic infiltration. In mice, Tc1 and Tc2 inhibit the IgE response Nevertheless, its contribution seems to be different in humans.
Hence, in atopic dermatitis allergen-specific Tc cells have been found to be elevated in blood and a cytotoxic activity has been detected in skin lesions that correlates with the intensity of the pathology , Besides, in allergic contact dermatitis against small peptides haptens there is a high percentage of Tc1 cells in injured tissues that show citotoxic activity against keratinocytes , In allergic asthma, Tc cells accumulate in lung after provocation with allergens and during acute episodes.
In cases of fatal asthma, a Tc infiltration in peribronquial tissue has been found. Other authors functionally divide Tc cells as effector or memory cells and describe that Tc2 type effectors contribute in a significant way to asthma through IL production It has also been found that TSLP, in association with CD40L, induces the formation of pro-allergenic Tc1 cells that contribute to the tissue inflammation Traditional treatment for allergy disorders includes drugs that prevent effects produced by mediators of inflammation or control inflammation in a non-specific way, to provide short time relief from disease symptoms.
Long term use of these palliative therapies is sometimes associated with adverse collateral effects. Identification of effector molecules that drive the inflammatory process in allergy has lead to the development of biological therapies directed to specifically block allergic pathways, or to enhance their natural regulatory mechanisms fig. The first biological agent used to treat allergy is a humanized monoclonal antibody, targeted to the C3 domain of the heavy chains of human IgE omalizumab.
This effect suggests that a significant component of the eosinophilia in allergic asthma is dependent on IgE Another therapeutic strategy to block IgE action consists of the administration of a primatized monoclonal antibody directed against CD This molecule seemed to reduce antigen presentation and Th2 response, but their therapeutical efficacy is still under study. Figure 4. Some human monoclonal antibodies have been generated to target different Th2 cytokines.
In the case of mepolizumab, a humanized monoclonal antibody against IL-5, its administration produces a strong and sustained reduction of circulating and airway eosinophil numbers. Despite these effects, early and late asthmatic reaction to allergen provocation was not affected. Weekly nebulisation of altrakincept, a recombinant of human soluble IL-4 receptor, prevented lung function decline and asthma exacerbations after abrupt withdrawal of inhaled corticosteroids. Therapies based on the administration of IL exert beneficial effects on allergic symptoms but might produce important side effects.
The recent identification of novel cytokines such as IL-6, IL, IL or TSLP, highly implicated in the immune process underlying allergy, offers new targets to control allergic inflammation. The evidence that in allergic diseases Treg cell function might be impaired, focuses current research on the design of therapies that generate an allergen-specific regulatory T-cell population with the potential to provide long-term improvement of disease symptoms.
Some strategies are based on the modification of dendritic cell function to obtain specific Treg cells 13, Other strategies exploit the fact that immunotherapy promotes Treg cells generation in a natural way and look for adjuvants from bacteria or helmints to potentiate this process 85, For example, the treatment of mice with a killed Mycobacterium vaccae-suspension gives rise to allergen-specific Treg cells, that confer protection against airway inflammation It has been observed that glucocorticoid treatment induces the generation of IL producing cells with regulatory properties.
These findings are being exploited to develop new curative therapies. Presently the allergic disease is considered as the result of an inappropriate balance between allergen activation of regulatory T cells and effector T helper 2 cells in susceptible individuals, a process in which dendritic cells are key players.
This lack of regulation in the immune response leads to an ongoing inflammatory process, in which different immune processes may follow one and other and accumulate over time. Nature , — Noval Rivas, M. Regulatory T cells in allergic diseases. Perrier, C.
Gut permeability and food allergies. Allergy 41 , 20—28 Williams, K. Anaphylaxis and urticaria. North Am. Khan, B. Pathophysiology of anaphylaxis. Pushparaj, P. The cytokine interleukin mediates anaphylactic shock. Natl Acad. USA , — Burton, O. Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy.
Mucosal Immunol. Gri, G. Immunity 29 , — Regulatory T cell reprogramming toward a TH2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity 42 , — Oral tolerance is another important programme of immune regulation against food antigens. In this paper, the important role of Treg cells is delineated. Vadas, P. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. Tordesillas, L. Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut.
Asero, R. Allergy 39 , — Platts-Mills, T. Anaphylaxis to the carbohydrate side chain alpha-gal. North Amer. Wilson, J. Commins, S. Tick bites and red meat allergy. Oettgen, H. Active anaphylaxis in IgE-deficient mice.
Finkelman, F. Lessons from mouse models. Leung, D. Effect of anti-IgE therapy in patients with peanut allergy. This is a key study demonstrating the benefit of pharmacotherapy directed against TH2-dependent immune pathways in this case, anti-IgE to modulate food allergy.
Brandt, E. Mast cells are required for experimental oral allergen-induced diarrhea. Mathias, C. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. Sampson, H. A practice parameter update Forbes, E.
IL and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. Induction of Interleukinproducing mucosal mast cells promotes susceptibility to IgE-mediated experimental food allergy. Immunity 43 , — Louahed, J. Interleukin-9 upregulates mucus expression in the airways. Respiratory Cell. Faulkner, H. Interleukin-9 enhances resistance to the intestinal nematode Trichuris muris. Infection Immun. Chang, H. The transcription factor PU.
Staudt, V. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33 , — Chatila, T. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol. Malbec, O. The mast cell IgG receptors and their roles in tissue inflammation.
Savilahti, E. Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes. Caubet, J. Patil, S. Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens.
Uermosi, C. Mechanisms of allergen-specific desensitization. Holt, P. Distinguishing benign from pathologic TH2 immunity in atopic children. Buhner, S. Mast cell-nerve axis with a focus on the human gut. Acta , 85—92 Abraham, S.
Mast cell-orchestrated immunity to pathogens. Zogaj, D. Exercise-induced anaphylaxis: the role of cofactors. Harada, S. Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Bauer, C. Heterogeneity in presentation and treatment of catamenial anaphylaxis. Greenhawt, M. The management of eosinophilic esophagitis. The journal of allergy and clinical immunology.
In Practice 1 , — Mishra, A. Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice. Foroughi, S. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. Rocha, R. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Clayton, F. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
Gastroenterology , — Aceves, S. Blanchard, C. IL involvement in eosinophilic esophagitis. Transcriptome analysis and reversibility with glucocorticoids. Esophageal remodeling in pediatric eosinophilic esophagitis.
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. Sherrill, J. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. Kottyan, L. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.
Sleiman, P. GWAS identifies four novel eosinophilic esophagitis loci. Litosh, V. Calpain and its association with eosinophilic esophagitis. Goldman, H. Allergic proctitis and gastroenteritis in children. Clinical and mucosal biopsy features in 53 cases. Boyce, J. Guidelines for the diagnosis and management of food allergy in the United States. This guideline is of clinical relevance for the diagnosis and management of food allergies in the United States.
Non-IgE-mediated gastrointestinal food allergies in children. Berin, M. Immunopathophysiology of food protein-induced enterocolitis syndrome. Chinthrajah, R. Molecular and cellular mechanisms of food allergy and food tolerance. Cerovic, V. Intestinal macrophages and dendritic cells. What's the difference? Trends Immunol. McDole, J. Hershberg, R. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells.
Rescigno, M. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Niess, J. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science , — Coombes, J. Iwata, M. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21 , — Elias, K.
Blood , — Worthington, J. Boyle, R. The development of food allergy after liver transplantation. Liver Transpl.
0コメント